bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Figure 5 from Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas
Authors: Cavalloni Giuliana , Peraldo-Neia Caterina , Sarotto Ivana , Gammaitoni Loretta , Migliardi Giorgia , Soster Marco , Marchiò Serena , Aglietta Massimo , Leone Francesco
Published: April 2023

PDF file, 19KB, TUNEL staining of BTC cell lines untreated (NT) and treated (SAR) with Saracatinib at the concentration of 5 �M for 24 hours. A statistical significant increase of apoptosis was seen in all the cell lines ( p-value < 0.05) except in HuH28.
Supplementary Figures from Synthetic Lethal Targeting of PTEN-Deficient Cancer Cells Using Selective Disruption of Polynucleotide Kinase/Phosphatase
Authors: Mereniuk Todd R. , El Gendy Mohamed A.M. , Mendes-Pereira Ana M. , Lord Christopher J. , Ghosh Sunita , Foley Edan , Ashworth Alan , Weinfeld Michael
Published: April 2023

PDF file, 110K, Supplementary Figure S1. Determination of ROS production in PTEN+/+ and PTEN-/- cells; Supplementary Figure S2. Cell proliferation assay of the PC3 derived cell lines.
Supplementary Figure Legend from Cotargeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer
Authors: Williams Terence M. , Flecha Athena R. , Keller Paul , Ram Ashwin , Karnak David , Galbán Stefanie , Galbán Craig J. , Ross Brian D. , Lawrence Theodore S. , Rehemtulla Alnawaz , Sebolt-Leopold Judith
Published: April 2023

PDF file, 44KB.
Supplementary Figure 3 from Antitumor Activity of Src Inhibitor Saracatinib (AZD-0530) in Preclinical Models of Biliary Tract Carcinomas
Authors: Cavalloni Giuliana , Peraldo-Neia Caterina , Sarotto Ivana , Gammaitoni Loretta , Migliardi Giorgia , Soster Marco , Marchiò Serena , Aglietta Massimo , Leone Francesco
Published: April 2023

PDF file, 28KB, Statistical analysis of reduction of cell proliferation by saracatinib in BTC cell lines. A statistical significant inhibition was revealed up to 1.25 �M in all the cell lines, except for TGBC1, in which no significance was found. In x-axis, doses of Saracatinib. In y-axis, absorbance.
Supplementary Figure Legend from The Inhibitor of Histone Deacetylases Sodium Butyrate Enhances the Cytotoxicity of Mitomycin C
Authors: Gospodinov Anastas , Popova Stanislava , Vassileva Ivelina , Anachkova Boyka
Published: April 2023

PDF file - 70K, Induction of ROS, DSB breaks and apoptosis in cells treated with vorinostat
Supplementary Video 1 from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models
Authors: Herter Sylvia , Herting Frank , Mundigl Olaf , Waldhauer Inja , Weinzierl Tina , Fauti Tanja , Muth Gunter , Ziegler-Landesberger Doris , Van Puijenbroek Erwin , Lang Sabine , Duong Minh Ngoc , Reslan Lina , Gerdes Christian A. , Friess Thomas , Baer Ute , Burtscher Helmut , Weidner Michael , Dumontet Charles , Umana Pablo , Niederfellner Gerhard , Bacac Marina , Klein Christian
Published: April 2023

WMV file - 14044K, Time-lapse imaging of direct cell death induction in Z138 lymphoma cells treated with either rituximab, ofatumumab, or GA101. Images were taken over 5.5 h of treatment. Annexin V FLUOS (detects phosphatidylserine exposure, green) and PI (detects loss of membrane integrity, red).
Supplementary Methods from Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab In Vitro and in Xenograft Models
Authors: Herter Sylvia , Herting Frank , Mundigl Olaf , Waldhauer Inja , Weinzierl Tina , Fauti Tanja , Muth Gunter , Ziegler-Landesberger Doris , Van Puijenbroek Erwin , Lang Sabine , Duong Minh Ngoc , Reslan Lina , Gerdes Christian A. , Friess Thomas , Baer Ute , Burtscher Helmut , Weidner Michael , Dumontet Charles , Umana Pablo , Niederfellner Gerhard , Bacac Marina , Klein Christian
Published: April 2023

PDF file - 100K
Supplementary Figure 2 from Modulation of p53 C-Terminal Acetylation by mdm2, p14ARF, and Cytoplasmic SirT2
Authors: van Leeuwen Ingeborg M.M. , Higgins Maureen , Campbell Johanna , McCarthy Anna R. , Sachweh Marijke C.C. , Navarro Ana Marín , Laín Sonia
Published: April 2023

PDF file - 114K, SirT1 downregulates total and nuclear acetylated p53
Supplementary Figure 5 from HER2-Targeted Hybrid Peptide That Blocks HER2 Tyrosine Kinase Disintegrates Cancer Cell Membrane and Inhibits Tumor Growth In Vivo
Authors: Kawamoto Megumi , Horibe Tomohisa , Kohno Masayuki , Kawakami Koji
Published: April 2023

PDF file - 58 KB, Cytotoxic activity of Her2-lytic hybrid peptide to cancer cells after the incubation with serum protein solution. HER2-lytic hybrid peptide was mixed with serum sample which was prepared from FBS for 0, 3, 6, 24 h, and then the mixtures were incubated with SK-BR-3 breast cancer cells at final concentration of HER2-lytic 10��M. The viability of these cells was measured using WST-8 solution as described in Materials and Methods section.
Supplementary Figure 1 from HER2-Targeted Hybrid Peptide That Blocks HER2 Tyrosine Kinase Disintegrates Cancer Cell Membrane and Inhibits Tumor Growth In Vivo
Authors: Kawamoto Megumi , Horibe Tomohisa , Kohno Masayuki , Kawakami Koji
Published: April 2023

PDF file - 64 KB, Effect on cell viability of anti-HER2 antibody and knockdown of HER2 by siRNA. (A) BT-474 and MDA-MB-231 cells were incubated with increasing concentrations of anti-HER2 monoclonal antibody for 3 h, and cytotoxicity was assessed using WST-8 reagent. Data are presented as means�}SD (error bars) from triplicate determinations. There was no statistical difference in the viability between cells with and without treatment with anti-HER2 antibody (60 ng/ml). (B) SK-BR-3, SK-OV-3, and PE cells were transfected without/with HER2 siRNA or scramble siRNA, and cytotoxicity was assessed using WST-8 reagent. Data are presented as means�}SD (error bars) from triplicate determinations. There was no statistical difference in the viability between no treatment and treatment with scramble and HER2 siRNA.
Supplementary Figure 4 from Targeting IGF-IR with Ganitumab Inhibits Tumorigenesis and Increases Durability of Response to Androgen-Deprivation Therapy in VCaP Prostate Cancer Xenografts
Authors: Fahrenholtz Cale D. , Beltran Pedro J. , Burnstein Kerry L.
Published: April 2023

PDF file - 106K, Assessment of full length AR and splice variant AR3 (AR-V7) transcript levels in VCaP xenografts treated with combined androgen-deprivation therapy (castration) and ganitumab
Supplementary Figure 6 from ATP Citrate Lyase Knockdown Induces Growth Arrest and Apoptosis through Different Cell- and Environment-Dependent Mechanisms
Authors: Zaidi Nousheen , Royaux Ines , Swinnen Johannes V. , Smans Karine
Published: April 2023

PDF file, 87KB, Growth curves for PC3M cells supplemented with Farnesyl pyrophosphate (FPP) Geranylgeranyl pyrophosphate (GGPP), oleic acid or cholesterol.
Supplementary Figure 1 from Cooperation between c-Met and Focal Adhesion Kinase Family Members in Medulloblastoma and Implications for Therapy
Authors: Guessous Fadila , Yang Yanzhi , Johnson Elizabeth , Marcinkiewicz Lukasz , Smith Matthew , Zhang Ying , Kofman Alexander , Schiff David , Christensen James , Abounader Roger
Published: April 2023

PDF file - 163K
Supplementary Figure 3 from ATP Citrate Lyase Knockdown Induces Growth Arrest and Apoptosis through Different Cell- and Environment-Dependent Mechanisms
Authors: Zaidi Nousheen , Royaux Ines , Swinnen Johannes V. , Smans Karine
Published: April 2023

PDF file, 188KB, Growth curves for PC3M derived shMock and shACLY-86 cells with /without IPTG induction in normal growth conditions; Absolute cell number for PC3M-derived shACLY-17, shACLY-86 and shMock cells grown in normal or lipid-reduced growth conditions with/without IPTG induction.
Supplementary Figure 1 from MK-2206, a Novel Allosteric Inhibitor of Akt, Synergizes with Gefitinib against Malignant Glioma via Modulating Both Autophagy and Apoptosis
Authors: Cheng Yan , Zhang Yi , Zhang Li , Ren Xingcong , Huber-Keener Kathryn J. , Liu Xiaoyuan , Zhou Lei , Liao Jason , Keihack Heike , Yan Li , Rubin Eric , Yang Jin-Ming
Published: April 2023

PDF file - 53K
Supplementary Figure 1 from Glycolytic Inhibition Alters Anaplastic Thyroid Carcinoma Tumor Metabolism and Improves Response to Conventional Chemotherapy and Radiation
Authors: Sandulache Vlad C. , Skinner Heath D. , Wang Yuan , Chen Yunyun , Dodge Cristina T. , Ow Thomas J. , Bankson James A. , Myers Jeffrey N. , Lai Stephen Y.
Published: April 2023

PDF file, 967KB.
Supplementary Table 2 from SAR131675, a Potent and Selective VEGFR-3–TK Inhibitor with Antilymphangiogenic, Antitumoral, and Antimetastatic Activities
Authors: Alam Antoine , Blanc Isabelle , Gueguen-Dorbes Geneviève , Duclos Olivier , Bonnin Jacques , Barron Pauline , Laplace Marie-Claude , Morin Gaelle , Gaujarengues Florence , Dol Frédérique , Hérault Jean-Pascal , Schaeffer Paul , Savi Pierre , Bono Françoise
Published: April 2023

PDF file - 93K, This file shows the effect of SAR131675 on a number of non-kinase enzymes, receptors and on ion channels
Supplementary Figure 3 from YM155 Reverses Cisplatin Resistance in Head and Neck Cancer by Decreasing Cytoplasmic Survivin Levels
Authors: Kumar Bhavna , Yadav Arti , Lang James C. , Cipolla Michael J. , Schmitt Alessandra C. , Arradaza Nicole , Teknos Theodoros N. , Kumar Pawan
Published: April 2023

PDF file, 2741KB, YM155 treatment induces survivin migration to nucleus in a time-dependent manner. CAL27-CisR cells were treated with YM155 (10 nM) for different time intervals and survvin localization was examined by staining these cells with survivin (red), β-catenin (green, membrane staining), and DAPI (blue, nucleus).
Supplementary Figure 1 from A Role for Homologous Recombination and Abnormal Cell-Cycle Progression in Radioresistance of Glioma-Initiating Cells
Authors: Lim Yi Chieh , Roberts Tara L. , Day Bryan W. , Harding Angus , Kozlov Sergei , Kijas Amanda W. , Ensbey Kathleen S. , Walker David G. , Lavin Martin F.
Published: April 2023

PDF file, 478K, Long-term proliferation and tumourigenicity in glioma initiating cells.
Supplementary Figure 1 from Overcoming Erlotinib Resistance in EGFR Mutation–Positive Non–Small Cell Lung Cancer Cells by Targeting Survivin
Authors: Okamoto Kunio , Okamoto Isamu , Hatashita Erina , Kuwata Kiyoko , Yamaguchi Haruka , Kita Aya , Yamanaka Kentaro , Ono Mayumi , Nakagawa Kazuhiko
Published: April 2023

PDF file - 73K
Supplementary Figure 1 from Synthetic Lethal Screening with Small-Molecule Inhibitors Provides a Pathway to Rational Combination Therapies for Melanoma
Authors: Roller Devin G. , Axelrod Mark , Capaldo Brian J. , Jensen Karin , Mackey Aaron , Weber Michael J. , Gioeli Daniel
Published: April 2023

PDF file, 428K, The combination of sorafenib and diclofenac causes cell death.
Supplementary Methods from Breast Cancer–Derived Bone Metastasis Can Be Effectively Reduced through Specific c-MET Inhibitor Tivantinib (ARQ 197) and shRNA c-MET Knockdown
Authors: Previdi Sara , Abbadessa Giovanni , Dalò Francesca , France Dennis S. , Broggini Massimo
Published: April 2023

PDF file - 89K
Supplementary Figure 1 from Sensitization of TRAIL-Induced Cell Death by 20(S)-Ginsenoside Rg3 via CHOP-Mediated DR5 Upregulation in Human Hepatocellular Carcinoma Cells
Authors: Lee Ju-Yeon , Jung Kyung Hee , Morgan Michael J. , Kang Yi-Rae , Lee Hee-Seung , Koo Gi-Bang , Hong Soon-Sun , Kwon Sung Won , Kim You-Sun
Published: April 2023

PDF file - 2112K, Short term Rg3 treatment is not cytotoxic in HepG2 cells
Supplementary Figure 3 from Tenovin-D3, a Novel Small-Molecule Inhibitor of Sirtuin SirT2, Increases p21 (CDKN1A) Expression in a p53-Independent Manner
Authors: McCarthy Anna R. , Sachweh Marijke C.C. , Higgins Maureen , Campbell Johanna , Drummond Catherine J. , van Leeuwen Ingeborg M.M. , Pirrie Lisa , Ladds Marcus J.G.W. , Westwood Nicholas J. , Laín Sonia
Published: April 2023

PDF file - 55K, Cell lines with differing p53 status were treated with tenovin-D3 for 8 hours.
Supplementary Figure 3 from Histone Deacetylase Regulation of ATM-Mediated DNA Damage Signaling
Authors: Thurn K. Ted , Thomas Scott , Raha Paromita , Qureshi Ian , Munster Pamela N.
Published: April 2023

PDF file, 206K, HDAC regulation of DNA repair gene expression.
Supplementary Figure Legend from Humanization of an Anti-CCR4 Antibody That Kills Cutaneous T-Cell Lymphoma Cells and Abrogates Suppression by T-Regulatory Cells
Authors: Chang De-Kuan , Sui Jianhua , Geng Shusheng , Muvaffak Asli , Bai Mei , Fuhlbrigge Robert C. , Lo Agnes , Yammanuru Anuradha , Hubbard Luke , Sheehan Jared , Campbell James J. , Zhu Quan , Kupper Thomas S. , Marasco Wayne A.
Published: April 2023

PDF file, 156K.
Supplementary Figure 1 from Histone Deacetylase Regulation of ATM-Mediated DNA Damage Signaling
Authors: Thurn K. Ted , Thomas Scott , Raha Paromita , Qureshi Ian , Munster Pamela N.
Published: April 2023

PDF file, 257K, HDAC inhibitor effect on DNA damage signaling.
Supplementary Figure Legends from PARP1 Is Overexpressed in Nasopharyngeal Carcinoma and Its Inhibition Enhances Radiotherapy
Authors: Chow Jeremy P.H. , Man Wing Yu , Mao Mao , Chen Han , Cheung Florence , Nicholls John , Tsao Sai Wah , Li Lung Maria , Poon Randy Y.C.
Published: April 2023

PDF - 54KB, Supplemental Figure legends
Supplementary Table 1 from Target-Based Therapeutic Matching in Early-Phase Clinical Trials in Patients with Advanced Colorectal Cancer and PIK3CA Mutations
Authors: Ganesan Prasanth , Janku Filip , Naing Aung , Hong David S. , Tsimberidou Apostolia M. , Falchook Gerald S. , Wheler Jennifer J. , Piha-Paul Sarina A. , Fu Siqing , Stepanek Vanda M. , Lee J. Jack , Luthra Rajyalakshmi , Overman Michael J. , Kopetz E. Scott , Wolff Robert A. , Kurzrock Razelle
Published: April 2023

PDF file - 66K, Target-matched therapy in patients with pik3ca mutations (n=17).
Supplementary Figure 2 from Targeting FoxM1 Effectively Retards p53-Null Lymphoma and Sarcoma
Authors: Wang Zebin , Zheng Yu , Park Hyun Jung , Li Jing , Carr Janai R. , Chen Yi-ju , Kiefer Megan M. , Kopanja Dragana , Bagchi Srilata , Tyner Angela L. , Raychaudhuri Pradip
Published: April 2023

PDF file - 107 KB, A, Representative pictures and quantification of soft agar colonies of CreERT2, Foxm1 fl/fl and p53 -/- sarcoma cells following control, 400nM and 800nM 4OH-tamoxifen treatment. B, Representative pictures and quantification of foci formation assay of CreERT2, Foxm1 fl/fl and p53 -/- sarcoma cells following control, 400nM and 800nM 4OH-tamoxifen treatment.
Supplementary Figure Legend 1 from MET Activation Mediates Resistance to Lapatinib Inhibition of HER2-Amplified Gastric Cancer Cells
Authors: Chen Chin-Tung , Kim Hyaehwan , Liska David , Gao Sizhi , Christensen James G. , Weiser Martin R.
Published: April 2023

PDF file - 177K
Supplementary Figures 1-4 from The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor
Authors: Kim Youngwook , Ko Jeonghun , Cui ZhengYun , Abolhoda Amir , Ahn Jin Seok , Ou Sai-Hong , Ahn Myung-Ju , Park Keunchil
Published: April 2023

PDF file - 1.9MB
Supplementary Figure 5 from Niclosamide Overcomes Acquired Resistance to Erlotinib through Suppression of STAT3 in Non–Small Cell Lung Cancer
Authors: Li Rui , Hu Zhongliang , Sun Shi-Yong , Chen Zhuo G. , Owonikoko Taofeek K. , Sica Gabriel L. , Ramalingam Suresh S. , Curran Walter J. , Khuri Fadlo R. , Deng Xingming
Published: April 2023

PDF file, 152K, Toxicity analysis for treatments with erlotinib and niclosamide in mice bearing HCC827/ER xenografts.
Supplementary Methods and Results from Targeted Degradation of KRAS by an Engineered Ubiquitin Ligase Suppresses Pancreatic Cancer Cell Growth In Vitro and In Vivo
Authors: Ma Yihui , Gu Yumei , Zhang Qiang , Han Yongqing , Yu Shuangni , Lu Zhaohui , Chen Jie
Published: April 2023

PDF file - 71KB, Supplementary file includes materials, methods and results of supplementary figure 1
Supplementary Figure 1 from SK-216, an Inhibitor of Plasminogen Activator Inhibitor-1, Limits Tumor Progression and Angiogenesis
Authors: Masuda Takeshi , Hattori Noboru , Senoo Tadashi , Akita Shin , Ishikawa Nobuhisa , Fujitaka Kazunori , Haruta Yoshinori , Murai Hiroshi , Kohno Nobuoki
Published: April 2023

PDF - 23KB, Structure of SK-216
Supplementary Figure 2 from Trans,trans,trans-[PtIV(N3)2(OH)2(py)(NH3)]: A Light-Activated Antitumor Platinum Complex That Kills Human Cancer Cells by an Apoptosis-Independent Mechanism
Authors: Westendorf Aron F. , Woods Julie A. , Korpis Katharina , Farrer Nicola J. , Salassa Luca , Robinson Kim , Appleyard Virginia , Murray Karen , Grünert Renate , Thompson Alastair M. , Sadler Peter J. , Bednarski Patrick J.
Published: April 2023

PDF file, 150KB, Effect of complex 3 on nuclear morphology of A2780 & A2780CIS cells.
Supplementary Figure 4 from Glycolysis Inhibition Sensitizes Non–Small Cell Lung Cancer with T790M Mutation to Irreversible EGFR Inhibitors via Translational Suppression of Mcl-1 by AMPK Activation
Authors: Kim Sun Mi , Yun Mi Ran , Hong Yun Kyoung , Solca Flavio , Kim Joo-Hang , Kim Hyun-Jung , Cho Byoung Chul
Published: April 2023

PDF file, 303K, Inhibition of glucose metabolism by the combined treatment with 2DG and afatinib does not affect transcription of Mcl-1.
Supplementary Figure 3 from Glycolysis Inhibition Sensitizes Non–Small Cell Lung Cancer with T790M Mutation to Irreversible EGFR Inhibitors via Translational Suppression of Mcl-1 by AMPK Activation
Authors: Kim Sun Mi , Yun Mi Ran , Hong Yun Kyoung , Solca Flavio , Kim Joo-Hang , Kim Hyun-Jung , Cho Byoung Chul
Published: April 2023

PDF file, 493K, Knockdown of Mcl-1 mimics the cytotoxicity by the combination of 2DG and afatinib.
Supplementary Table 1 from Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
Authors: Davies Barry R. , Greenwood Hannah , Dudley Phillippa , Crafter Claire , Yu De-Hua , Zhang Jingchuan , Li Jing , Gao Beirong , Ji Qunsheng , Maynard Juliana , Ricketts Sally-Ann , Cross Darren , Cosulich Sabina , Chresta Christine C. , Page Ken , Yates James , Lane Clare , Watson Rebecca , Luke Richard , Ogilvie Donald , Pass Martin
Published: April 2023

XLS file - 82K, Details of cell lines.
Supplementary Figure 2 from Preclinical Pharmacology of AZD5363, an Inhibitor of AKT: Pharmacodynamics, Antitumor Activity, and Correlation of Monotherapy Activity with Genetic Background
Authors: Davies Barry R. , Greenwood Hannah , Dudley Phillippa , Crafter Claire , Yu De-Hua , Zhang Jingchuan , Li Jing , Gao Beirong , Ji Qunsheng , Maynard Juliana , Ricketts Sally-Ann , Cross Darren , Cosulich Sabina , Chresta Christine C. , Page Ken , Yates James , Lane Clare , Watson Rebecca , Luke Richard , Ogilvie Donald , Pass Martin
Published: April 2023

PDF file - 81K, Correlation of AZD5363 activity in cell lines from different tumor types with PIK3CA and PTEN mutation status.
Supplementary Figure 6 from Evidence for the Ubiquitin Protease UBP43 as an Antineoplastic Target
Authors: Guo Yongli , Chinyengetere Fadzai , Dolinko Andrey V. , Lopez-Aguiar Alexandra , Lu Yun , Galimberti Fabrizio , Ma Tian , Feng Qing , Sekula David , Freemantle Sarah J. , Andrew Angeline S. , Memoli Vincent , Dmitrovsky Ethan
Published: April 2023

PDF file, 79K, UBP43 is up-regulated in diverse human cancers as compared to corresponding normal tissues.
Supplementary Figure 3 from Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
Authors: Maira Sauveur-Michel , Pecchi Sabina , Huang Alan , Burger Matthew , Knapp Mark , Sterker Dario , Schnell Christian , Guthy Daniel , Nagel Tobi , Wiesmann Marion , Brachmann Saskia , Fritsch Christine , Dorsch Marion , Chène Patrick , Shoemaker Kevin , De Pover Alain , Menezes Daniel , Martiny-Baron Georg , Fabbro Doriano , Wilson Christopher J. , Schlegel Robert , Hofmann Francesco , García-Echeverría Carlos , Sellers William R. , Voliva Charles F.
Published: April 2023

PDF file - 215K
Supplementary Figure 1 from Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
Authors: Maira Sauveur-Michel , Pecchi Sabina , Huang Alan , Burger Matthew , Knapp Mark , Sterker Dario , Schnell Christian , Guthy Daniel , Nagel Tobi , Wiesmann Marion , Brachmann Saskia , Fritsch Christine , Dorsch Marion , Chène Patrick , Shoemaker Kevin , De Pover Alain , Menezes Daniel , Martiny-Baron Georg , Fabbro Doriano , Wilson Christopher J. , Schlegel Robert , Hofmann Francesco , García-Echeverría Carlos , Sellers William R. , Voliva Charles F.
Published: April 2023

PDF file - 419K
Supplementary Figure 4 from First Evidence of Sphingosine 1-Phosphate Lyase Protein Expression and Activity Downregulation in Human Neoplasm: Implication for Resistance to Therapeutics in Prostate Cancer
Authors: Brizuela Leyre , Ader Isabelle , Mazerolles Catherine , Bocquet Magalie , Malavaud Bernard , Cuvillier Olivier
Published: April 2023

PDF file, 78K, S1P degradation products do not sensitize to radiotherapy or chemotherapy in PC-3 and C4-2B prostate cancer cells.
Supplementary Figure 3 from First Evidence of Sphingosine 1-Phosphate Lyase Protein Expression and Activity Downregulation in Human Neoplasm: Implication for Resistance to Therapeutics in Prostate Cancer
Authors: Brizuela Leyre , Ader Isabelle , Mazerolles Catherine , Bocquet Magalie , Malavaud Bernard , Cuvillier Olivier
Published: April 2023

PDF file, 136K, The silencing of SphK2 activity does not sensitize to docetaxel nor to radiotherapy in PC-3 and C4-2B cell lines.
Supplementary Figure 1 from Targeting Subcellular Localization through the Polo-Box Domain: Non-ATP Competitive Inhibitors Recapitulate a PLK1 Phenotype
Authors: McInnes Campbell , Estes Kara , Baxter Merissa , Yang Zhengguan , Farag Doaa Boshra , Johnston Paul , Lazo John S. , Wang Jianjun , Wyatt Michael D.
Published: April 2023

PDF file - 304K, Dose-response IC 50 Curves for PBD Inhibitors
Supplementary Table 2 from Contrary Regulation of Bladder Cancer Cell Proliferation and Invasion by Dexamethasone-Mediated Glucocorticoid Receptor Signals
Authors: Zheng Yichun , Izumi Koji , Li Yi , Ishiguro Hitoshi , Miyamoto Hiroshi
Published: April 2023

PDF file - 57K, Sequences of primers used for RT-PCR analysis
Supplementary Figure 1 from Simultaneous Targeting of COX-2 and AKT Using Selenocoxib-1-GSH to Inhibit Melanoma
Authors: Gowda Raghavendra , Madhunapantula SubbaRao V. , Desai Dhimant , Amin Shantu , Robertson Gavin P.
Published: April 2023

PDF file - 132K, Selenocoxib-1-GSH does not alter the cellular or morphological organization of organs in animals following treatment
Supplementary Figure 1 from The HSP70 and Autophagy Inhibitor Pifithrin-μ Enhances the Antitumor Effects of TRAIL on Human Pancreatic Cancer
Authors: Monma Hiroyuki , Harashima Nanae , Inao Touko , Okano Shinji , Tajima Yoshitsugu , Harada Mamoru
Published: April 2023

PDF file - 94K, Expression of DR4 and DR5 on human panreatic cancer cell lines
Supplementary Figure 5 from Single-Chain Antibody-Based Immunotoxins Targeting Her2/neu: Design Optimization and Impact of Affinity on Antitumor Efficacy and Off-Target Toxicity
Authors: Cao Yu , Marks James D. , Huang Qian , Rudnick Stephen I. , Xiong Chiyi , Hittelman Walter N. , Wen Xiaoxia , Marks John W. , Cheung Lawrence H. , Boland Kim , Li Chun , Adams Gregory P. , Rosenblum Michael G.
Published: April 2023

PDF file - 1877KB, Statistical comparisons of Tissue-to-Muscle Ratio (tumor or liver to muscle ratio) of IRDye800-MH3-B1/rGel and IRDye800-B1D3/rGel after 24h (A) and 72h (B) injection to BT474 M1 xenograft tumors.
Supplementary Figure 2 from Targeting KRAS-Mutant Non–Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib
Authors: Acquaviva Jaime , Smith Donald L. , Sang Jim , Friedland Julie C. , He Suqin , Sequeira Manuel , Zhang Chaohua , Wada Yumiko , Proia David A.
Published: April 2023

PDF file - 864K, In vivo activity of ganetespib in combination with AZD6244 in A549 xenografts
Supplementary Figure 1 from Targeting KRAS-Mutant Non–Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib
Authors: Acquaviva Jaime , Smith Donald L. , Sang Jim , Friedland Julie C. , He Suqin , Sequeira Manuel , Zhang Chaohua , Wada Yumiko , Proia David A.
Published: April 2023

PDF file - 890K, Combinations of ganetespib with MEK and PI3K/mTOR inhibitors in vitro
Supplementary Table 5 from DNA Methyltransferase Inhibitor, Zebularine, Delays Tumor Growth and Induces Apoptosis in a Genetically Engineered Mouse Model of Breast Cancer
Authors: Chen Min , Shabashvili Daniel , Nawab Akbar , Yang Sherry X. , Dyer Lisa M. , Brown Kevin D. , Hollingshead Melinda , Hunter Kent W. , Kaye Frederic J. , Hochwald Steven N. , Marquez Victor E. , Steeg Patricia , Zajac-Kaye Maria
Published: April 2023

PDF file - 396K, Differentially up-regulated genes (>1.5-fold differences; P < 0.05) from mammary tumors of the PyMT transgenic mice exposed to zebularine for 48 days.
Supplementary Methods, Tables 1-5, Figures 1-9 from Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302
Authors: Meng Fanying , Evans James W. , Bhupathi Deepthi , Banica Monica , Lan Leslie , Lorente Gustavo , Duan Jian-Xin , Cai Xiaohong , Mowday Alexandra M. , Guise Christopher P. , Maroz Andrej , Anderson Robert F. , Patterson Adam V. , Stachelek Gregory C. , Glazer Peter M. , Matteucci Mark D. , Hart Charles P.
Published: April 2023

PDF file - 481K
Supplementary Table 2 from DNA Methyltransferase Inhibitor, Zebularine, Delays Tumor Growth and Induces Apoptosis in a Genetically Engineered Mouse Model of Breast Cancer
Authors: Chen Min , Shabashvili Daniel , Nawab Akbar , Yang Sherry X. , Dyer Lisa M. , Brown Kevin D. , Hollingshead Melinda , Hunter Kent W. , Kaye Frederic J. , Hochwald Steven N. , Marquez Victor E. , Steeg Patricia , Zajac-Kaye Maria
Published: April 2023

PDF file - 428K, Differentially down-regulated genes (>1.5-fold differences; P < 0.05) from mammary tumors of the PyMT transgenic mice exposed to zebularine for 13 days.
Supplementary Figure 2 from Microtubule Dynamics Control Tail Retraction in Migrating Vascular Endothelial Cells
Authors: Ganguly Anutosh , Yang Hailing , Zhang Hong , Cabral Fernando , Patel Kamala D.
Published: April 2023

PDF file - 187K, Supplementary figure 2. Immunofluorescence microscopy of drug treated HUVEC.
Supplementary Table 5 from BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application
Authors: Siemeister Gerhard , Lücking Ulrich , Wengner Antje M. , Lienau Philip , Steinke Wolfram , Schatz Christoph , Mumberg Dominik , Ziegelbauer Karl
Published: April 2023

PDF file, 57K, Pharmacokinetic data.
Supplementary Figure 1 from BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application
Authors: Siemeister Gerhard , Lücking Ulrich , Wengner Antje M. , Lienau Philip , Steinke Wolfram , Schatz Christoph , Mumberg Dominik , Ziegelbauer Karl
Published: April 2023

PDF file, 46K, Exposure kinetics of BAY 1000394.
Supplementary Figure 1 from HER2 As Therapeutic Target for Overcoming ATP-Binding Cassette Transporter–Mediated Chemoresistance in Small Cell Lung Cancer
Authors: Minami Toshiyuki , Kijima Takashi , Otani Yasushi , Kohmo Satoshi , Takahashi Ryo , Nagatomo Izumi , Hirata Haruhiko , Suzuki Mayumi , Inoue Koji , Takeda Yoshito , Kida Hiroshi , Tachibana Isao , Kumanogoh Atsushi
Published: April 2023

PDF file - 82K, Lapatinib monotherapy does not inhibit the proliferation of HER2-positive SCLC cells. SCLC cells (H69, SBC-3, SBC-3/CDDP, SBC-3/ETP, SBC-3/SN-38 and SBC-5) and breast carcinoma cells (SK-BR-3) were treated with lapatinib for 72 h. Lapatinib inhibited proliferation of breast carcinoma cells, however, could not inhibit proliferation of SCLC cells at clinically achievable concentration regardless of the amount of HER2 expression.
Supplementary Figure 3 from Bortezomib Sensitizes Human Acute Myeloid Leukemia Cells to All-Trans-Retinoic Acid–Induced Differentiation by Modifying the RARα/STAT1 Axis
Authors: Ying Meidan , Zhou Xinglu , Zhong Like , Lin Nengming , Jing Hui , Luo Peihua , Yang Xiaochun , Song Hua , Yang Bo , He Qiaojun
Published: April 2023

PDF file - 2686K, The effect of bortezomib (BTZ) and ATRA on RARα expression and NBT reduction ability in HL60-vector and HL60-shRNA-STAT1 cells.
Supplementary Figure 6 from Characterization of a New Class of Androgen Receptor Antagonists with Potential Therapeutic Application in Advanced Prostate Cancer
Authors: Li Huifang , Hassona Mohamed D.H. , Lack Nathan A. , Axerio-Cilies Peter , Leblanc Eric , Tavassoli Peyman , Kanaan Natalia , Frewin Kate , Singh Kriti , Adomat Hans , Böhm Konrad J. , Prinz Helge , Guns Emma Tomlinson , Rennie Paul S. , Cherkasov Artem
Published: April 2023

PDF file, 1976K, (A) Inhibition of in vitro polymerization of tubulin at 37 {degree sign}C by various concentrations of VPC-3033; turbidity was recorded at 360 nM.The steady-state tubulin assembly level in the absence of inhibitor was set at 100%. (B) IC50 values were determined by sigmoidal fitting of the plot of the steady state levels of tubulin assembly (taken after 45 min) aginst drug concentration and represent the concentration for 50% inhibition of the maximum tubulin polymerization level.
Supplementary Figure 3 from Antitumor Activity of a Duocarmycin Analogue Rationalized to Be Metabolically Activated by Cytochrome P450 1A1 in Human Transitional Cell Carcinoma of the Bladder
Authors: Sutherland Mark , Gill Jason H. , Loadman Paul M. , Laye Jonathan P. , Sheldrake Helen M. , Illingworth Nicola A. , Alandas Mohammed N. , Cooper Patricia A. , Searcey Mark , Pors Klaus , Shnyder Steve D. , Patterson Laurence H.
Published: April 2023

PDF file - 156K, Chromatogram of metabolite profile of ICT2700 incubated with human ex vivo liver microsomes demonstrating there is no evidence for the appearance of the cytotoxic metabolite ICT2740
Supplementary Figure 1 from CK2 Inhibitor CX-4945 Suppresses DNA Repair Response Triggered by DNA-Targeted Anticancer Drugs and Augments Efficacy: Mechanistic Rationale for Drug Combination Therapy
Authors: Siddiqui-Jain Adam , Bliesath Joshua , Macalino Diwata , Omori Mayuko , Huser Nanni , Streiner Nicole , Ho Caroline B. , Anderes Kenna , Proffitt Chris , O'Brien Sean E. , Lim John K. C. , Von Hoff Daniel D. , Ryckman David M. , Rice William G. , Drygin Denis
Published: April 2023

PDF file - 97K, Quantified western blots for Gamma-H2AX and cleaved PARP levels normalized to �eta-actin levels from cisplatin or gemcitabine combinations with CX-4945.
Supplementary Figure 3 from IGF-1R/MDM2 Relationship Confers Enhanced Sensitivity to RITA in Ewing Sarcoma Cells
Authors: Di Conza Giusy , Buttarelli Marianna , Monti Olimpia , Pellegrino Marsha , Mancini Francesca , Pontecorvi Alfredo , Scotlandi Katia , Moretti Fabiola
Published: April 2023

PDF file, 31KB, IGF-1R and MDM2 protein levels upon RITA treatment in LAP-35 and 6647 cells.
Supplementary Figure 2 from Plk1 Phosphorylation of Orc2 and Hbo1 Contributes to Gemcitabine Resistance in Pancreatic Cancer
Authors: Song Bing , Liu X. Shawn , Rice Steven J. , Kuang Shihuan , Elzey Bennett D. , Konieczny Stephen F. , Ratliff Timothy L. , Hazbun Tony , Chiorean Elena G. , Liu Xiaoqi
Published: April 2023

PDF file - 102K, Gemcitabine-resistant tumors are sensitive to inhibition of Plk1
Supplementary Figure Legend from Long Pentraxin-3 Inhibits Epithelial–Mesenchymal Transition in Melanoma Cells
Authors: Ronca Roberto , Di Salle Emanuela , Giacomini Arianna , Leali Daria , Alessi Patrizia , Coltrini Daniela , Ravelli Cosetta , Matarazzo Sara , Ribatti Domenico , Vermi William , Presta Marco
Published: April 2023

PDF - 44KB, Legends to Supplementary Figures S1-S4.
Supplementary Figure 2 from Long Pentraxin-3 Inhibits Epithelial–Mesenchymal Transition in Melanoma Cells
Authors: Ronca Roberto , Di Salle Emanuela , Giacomini Arianna , Leali Daria , Alessi Patrizia , Coltrini Daniela , Ravelli Cosetta , Matarazzo Sara , Ribatti Domenico , Vermi William , Presta Marco
Published: April 2023

PDF - 114KB, Morphogenic assay on Matrigel.
Supplementary Figure 1 from Betulinic Acid Targets YY1 and ErbB2 through Cannabinoid Receptor-Dependent Disruption of MicroRNA-27a:ZBTB10 in Breast Cancer
Authors: Liu Xinyi , Jutooru Indira , Lei Ping , Kim KyoungHyun , Lee Syng-ook , Brents Lisa K. , Prather Paul L. , Safe Stephen
Published: April 2023

PDF file, 200KB, Role of Sp proteins in regulating level of YY1 protein.
Supplementary Figures 1-7 from Capillary Isoelectric-Focusing Immunoassays to Study Dynamic Oncoprotein Phosphorylation and Drug Response to Targeted Therapies in Non–Small Cell Lung Cancer
Authors: Chen Jin-Qiu , Lee Jih-Hsiang , Herrmann Michelle A. , Park Kang-Seo , Heldman Madeleine R. , Goldsmith Paul K. , Wang Yisong , Giaccone Giuseppe
Published: April 2023

PDF - 611KB, Supplementary Figure S1. Phospho-ERK1/2 signal response to erlotinib treatment in mouse tissues; Supplementary Figure S2. Response in NSCLC cell to MEK inhibitor PD325901 treatment; Supplementary Figure S3. Quantitation of MEK signal response in NSCLC cells treated with MEK inhibitor PD325901; Supplementary Figure S4. MEK1/2 peak assignments determined using isoform and phospho-specific anti-MEK antibodies; Supplementary Figure S5. Cell viability assay of lung adenocarcinoma cells with erlotinib treatment; Supplementary Figure S6. MEK2 siRNA knockdown in HCC827 cells; Supplementary Figure S7. Signaling molecule responses in a lung carcinoma patient treated with erlotinib and AZD6244
Supplementary Figure 1 from Novel Immunotherapy for Malignant Melanoma with a Monoclonal Antibody That Blocks CEACAM1 Homophilic Interactions
Authors: Ortenberg Rona , Sapir Yair , Raz Lee , Hershkovitz Liat , Ben Arav Ayelet , Sapoznik Sivan , Barshack Iris , Avivi Camila , Berkun Yackov , Besser Michal J. , Ben-Moshe Tehila , Schachter Jacob , Markel Gal
Published: April 2023

PDF file, 277KB, MRG1 specifically recognizes the N-domain of the CEACAM1 protein and has a high binding affinity.
Supplementary Figure 2 from Fibroblast Growth Factor Receptor 2 IIIc as a Therapeutic Target for Colorectal Cancer Cells
Authors: Matsuda Yoko , Hagio Masahito , Seya Tomoko , Ishiwata Toshiyuki
Published: April 2023

PDF file, 613K, A, Effects of monoclonal anti-FGFR2IIIc antibody in FGFR2IIIc overexpressing DLD-1 cells. B, Effects of siRNA targeting FGFR2IIIc in LoVo cells.
Supplementary Figure 6 from Combined Therapy with Mutant-Selective EGFR Inhibitor and Met Kinase Inhibitor for Overcoming Erlotinib Resistance in EGFR-Mutant Lung Cancer
Authors: Nakagawa Takayuki , Takeuchi Shinji , Yamada Tadaaki , Nanjo Shigeki , Ishikawa Daisuke , Sano Takako , Kita Kenji , Nakamura Takahiro , Matsumoto Kunio , Suda Kenichi , Mitsudomi Tetsuya , Sekido Yoshitaka , Uenaka Toshimitsu , Yano Seiji
Published: April 2023

PDF file, 138K, Supplementary Figure S6 Treatment with WZ4002 and/or E7050 does not induce apoptosis in vivo.
Supplementary Figure 2 from Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy
Authors: Ying Weiwen , Du Zhenjian , Sun Lijun , Foley Kevin P. , Proia David A. , Blackman Ronald K. , Zhou Dan , Inoue Takayo , Tatsuta Noriaki , Sang Jim , Ye Shuxia , Acquaviva Jamie , Ogawa Luisa Shin , Wada Yumiko , Barsoum James , Koya Keizo
Published: April 2023

PDF file - 98K
Supplementary Figure 5 from MAPK Pathway Inhibition Enhances the Efficacy of an Anti-Endothelin B Receptor Drug Conjugate by Inducing Target Expression in Melanoma
Authors: Asundi Jyoti , Lacap Jennifer A. , Clark Suzanna , Nannini Michelle , Roth Leslie , Polakis Paul
Published: April 2023

PDF file - 222KB, in vivo PD response.
Supplementary figure legends from 2-Deoxy-Glucose Downregulates Endothelial AKT and ERK via Interference with N-Linked Glycosylation, Induction of Endoplasmic Reticulum Stress, and GSK3β Activation
Authors: Kovács Krisztina , Decatur Christina , Toro Marcela , Pham Dien G. , Liu Huaping , Jing Yuqi , Murray Timothy G. , Lampidis Theodore J. , Merchan Jaime R.
Published: April 2023

Legends for Fig S1 to S3.
Figs S1, S2, S3 from 2-Deoxy-Glucose Downregulates Endothelial AKT and ERK via Interference with N-Linked Glycosylation, Induction of Endoplasmic Reticulum Stress, and GSK3β Activation
Authors: Kovács Krisztina , Decatur Christina , Toro Marcela , Pham Dien G. , Liu Huaping , Jing Yuqi , Murray Timothy G. , Lampidis Theodore J. , Merchan Jaime R.
Published: April 2023

FIG. S-1. Effects of 2-DG on tumor angiogenesis in vivo in the LHBETATAG model of retinoblastoma. FIG. S-2. Quantitative analysis of the effects of 2-DG on tumor GRP-78 expression. FIG. S-3. Effects of 2-DG treatment on ER stress markers Laser capture microdissection tissues.
Supplementary Figure 3 from Pharmacologic Inhibition of MEK Signaling Prevents Growth of Canine Hemangiosarcoma
Authors: Andersen Nicholas J. , Nickoloff Brian J. , Dykema Karl J. , Boguslawski Elissa A. , Krivochenitser Roman I. , Froman Roe E. , Dawes Michelle J. , Baker Laurence H. , Thomas Dafydd G. , Kamstock Debra A. , Kitchell Barbara E. , Furge Kyle A. , Duesbery Nicholas S.
Published: April 2023

PDF file - 146K, Supplemental Figure S3. Reduction of phospho-ERK1/2 IHC staining of cutaneous-derived xenograft and cardiac-derived tumorgraft treated with sorafenib.
Supplementary Figure 2 from Pharmacologic Inhibition of MEK Signaling Prevents Growth of Canine Hemangiosarcoma
Authors: Andersen Nicholas J. , Nickoloff Brian J. , Dykema Karl J. , Boguslawski Elissa A. , Krivochenitser Roman I. , Froman Roe E. , Dawes Michelle J. , Baker Laurence H. , Thomas Dafydd G. , Kamstock Debra A. , Kitchell Barbara E. , Furge Kyle A. , Duesbery Nicholas S.
Published: April 2023

PDF file - 142K, Supplemental Figure S2. Reduction of phospho-ERK1/2 IHC staining of cutaneous-derived xenograft and cardiac-derived tumorgraft treated with CI-1040.
Supplementary Tables from The IGF-Trap: Novel Inhibitor of Carcinoma Growth and Metastasis
Authors: Wang Ni , Rayes Roni F. , Elahi Seyyed Mehdy , Lu Yifan , Hancock Mark A. , Massie Bernard , Rowe Gerald E. , Aomari Hafida , Hossain Sazzad , Durocher Yves , Pinard Maxime , Tabariès Sébastien , Siegel Peter M. , Brodt Pnina
Published: April 2023

This document contains Table S1 to S3
Supplementary Figure S5 from The IGF-Trap: Novel Inhibitor of Carcinoma Growth and Metastasis
Authors: Wang Ni , Rayes Roni F. , Elahi Seyyed Mehdy , Lu Yifan , Hancock Mark A. , Massie Bernard , Rowe Gerald E. , Aomari Hafida , Hossain Sazzad , Durocher Yves , Pinard Maxime , Tabariès Sébastien , Siegel Peter M. , Brodt Pnina
Published: April 2023

Plasma insulin levels are not markedly altered in IGF-Trap injected mice
Supplementary figure 2 from TPCA-1 Is a Direct Dual Inhibitor of STAT3 and NF-κB and Regresses Mutant EGFR-Associated Human Non–Small Cell Lung Cancers
Authors: Nan Jing , Du Yuping , Chen Xing , Bai Qifeng , Wang Yuxin , Zhang Xinxin , Zhu Ning , Zhang Jing , Hou Jianwen , Wang Qin , Yang Jinbo
Published: April 2023

Dose dependent effects of TPCA-1 on STAT3 activation.
Supplementary Figure Legends from The IGF-Trap: Novel Inhibitor of Carcinoma Growth and Metastasis
Authors: Wang Ni , Rayes Roni F. , Elahi Seyyed Mehdy , Lu Yifan , Hancock Mark A. , Massie Bernard , Rowe Gerald E. , Aomari Hafida , Hossain Sazzad , Durocher Yves , Pinard Maxime , Tabariès Sébastien , Siegel Peter M. , Brodt Pnina
Published: April 2023

This documents contains the legends of Figures 1 to S6
Supplementary Materials and Methods, Supplementary Figure Legend, and Supplementary Figures 1 through 4 from Activation of Peroxisome Proliferator-Activated Receptor-β/δ (PPAR-β/δ) Inhibits Human Breast Cancer Cell Line Tumorigenicity
Authors: Yao Pei-Li , Morales Jose L. , Zhu Bokai , Kang Boo-Hyon , Gonzalez Frank J. , Peters Jeffrey M.
Published: April 2023

PDF - 587K, Supplementary Materials and Methods; Supplementary Figure Legend. Supplementary Fig. 1. The effect of over-expressing and/or ligand activation of PPAR/ on cell cycle progression in MDA-MB-231 and MCF7 cells. Supplementary Fig. 2. The effect of over-expressing PPARbeta/? and/or ligand activation of PPARbeta/? on staurosporine induced PARP cleavage in MDA-MB-231 and MCF7 cells. Supplementary Fig. 3. The effect of over-expressing PPARbeta/? and/or ligand activation of PPARbeta/? on UVB-induced PARP cleavage in MDA-MB-231 and MCF7 cells. Supplementary Fig. 4. The effect of over-expressing PPARbeta/? and/or ligand activation of PPARbeta/? on xenograft histopathology and necrosis.
Supplementary Materials and Methods and Supplementary Figure Legends from CBS9106-Induced CRM1 Degradation Is Mediated by Cullin Ring Ligase Activity and the Neddylation Pathway
Authors: Saito Naoya , Sakakibara Keiichi , Sato Takuji , Friedman Jonathan M. , Kufe Donald W. , VonHoff Daniel D. , Kawabe Takumi
Published: April 2023

Supplementary materials and methods and Supplementary figure legends
Data Supplement from A Bispecific HER2-Targeting FynomAb with Superior Antitumor Activity and Novel Mode of Action
Authors: Brack Simon , Attinger-Toller Isabella , Schade Babette , Mourlane Frédéric , Klupsch Kristina , Woods Richard , Hachemi Helen , von der Bey Ulrike , Koenig-Friedrich Susann , Bertschinger Julian , Grabulovski Dragan
Published: April 2023

Figure S1: Characterization of binding properties and thermal stability of Fynomer C12; Figure S2: Results of binding studies with C12-pertuzumab bispecific FynomAbs; Figure S3: Additional in vitro tumour growth inhibition studies with COVA208 on more HER2 positive cancer cell lines; Figure S4: Additional data on the induction of apoptosis in NCI-N87 cells by COVA208: dose-response curve of Caspase 3/7 activity, and Tunel assay; Figure S5: Expression data (heat map) of signalling mediators in response to treatment with COVA208, pertuzumab, or trastuzumab (RPPA analysis); Supplementary Table 1 listing expression data of 167 signaling proteins (phospho- and total proteins) in response to COVA208, pertuzumab or trastuzumab treatment of NCI-N87 cells in vitro.
Data Supplement from A Bispecific HER2-Targeting FynomAb with Superior Antitumor Activity and Novel Mode of Action
Authors: Brack Simon , Attinger-Toller Isabella , Schade Babette , Mourlane Frédéric , Klupsch Kristina , Woods Richard , Hachemi Helen , von der Bey Ulrike , Koenig-Friedrich Susann , Bertschinger Julian , Grabulovski Dragan
Published: April 2023

Includes Supplementary Methods: - Cell culture - Expression, purification and characterisation of bispecific FynomAbs and pertuzumab -Tunel assay -Internalization assays -Immunoblot analysis of cell lysates and tumor samples -Antibody-dependent cellular cytotoxicity assay -Pharmacokinetics of COVA208 -in vivo tumor xenograft models - Preparation of tumours for PD analysis - BIAcore real time interaction analysis - FACS binding assays - Epitope mapping - CD spectroscopy - Reverse phase protein array (RPPA) analysis of NCI-N87 cell lysates
Supplementary Figure 4 from CBS9106-Induced CRM1 Degradation Is Mediated by Cullin Ring Ligase Activity and the Neddylation Pathway
Authors: Saito Naoya , Sakakibara Keiichi , Sato Takuji , Friedman Jonathan M. , Kufe Donald W. , VonHoff Daniel D. , Kawabe Takumi
Published: April 2023

Supplementary Figure 4: The cell growth inhibition by CBS9106 is suppressed by MLN4924 in colon cancer cells. HT29 cells (A) and HCT15 (B) are treated with CBS9106 (50 or 100 nM) or MLN4924 (1, 10, or 50 nM) either alone or in combination for 72 hours (n = 6). Cell viability is determined by cell counting kit-8. Data are expressed as the mean {plus minus} SD. *P<0.05.
Supplementary Figure Legends from βIII-Tubulin Regulates Breast Cancer Metastases to the Brain
Authors: Kanojia Deepak , Morshed Ramin A. , Zhang Lingjiao , Miska Jason M. , Qiao Jian , Kim Julius W. , Pytel Peter , Balyasnikova Irina V. , Lesniak Maciej S. , Ahmed Atique U.
Published: April 2023

Full information pertaining to supplementary figure legends.
Supplementary Figure 1 from βIII-Tubulin Regulates Breast Cancer Metastases to the Brain
Authors: Kanojia Deepak , Morshed Ramin A. , Zhang Lingjiao , Miska Jason M. , Qiao Jian , Kim Julius W. , Pytel Peter , Balyasnikova Irina V. , Lesniak Maciej S. , Ahmed Atique U.
Published: April 2023

Generation of TUBB3 knockdown cells.
Supplemental Figure 3 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume
Authors: Theodosakis Nicholas , Held Matthew A. , Marzuka-Alcala Alexander , Meeth Katrina M. , Micevic Goran , Long Georgina V. , Scolyer Richard A. , Stern David F. , Bosenberg Marcus W.
Published: April 2023

Supplemental Figure 3. Adherent cell area pre- vs. post-treatment
Supplemental Figure 1 from BRAF Inhibition Decreases Cellular Glucose Uptake in Melanoma in Association with Reduction in Cell Volume
Authors: Theodosakis Nicholas , Held Matthew A. , Marzuka-Alcala Alexander , Meeth Katrina M. , Micevic Goran , Long Georgina V. , Scolyer Richard A. , Stern David F. , Bosenberg Marcus W.
Published: April 2023

Supplemental Figure 1. Characterization of drug response
Supplementary Legends from RNA Interference Using c-Myc–Conjugated Nanoparticles Suppresses Breast and Colorectal Cancer Models
Authors: Tangudu Naveen K. , Verma Vinod K. , Clemons Tristan D. , Beevi Syed S. , Hay Trevor , Mahidhara Ganesh , Raja Meera , Nair Rekha A. , Alexander Liza E. , Patel Anant B. , Jose Jedy , Smith Nicole M. , Zdyrko Bogdan , Bourdoncle Anne , Luzinov Igor , Iyer K. Swaminathan , Clarke Alan R. , Dinesh Kumar Lekha
Published: April 2023

Supplementary tables Table S1 & Table S2 and legends for supplementary figures
Supplementary Figure S6 from RNA Interference Using c-Myc–Conjugated Nanoparticles Suppresses Breast and Colorectal Cancer Models
Authors: Tangudu Naveen K. , Verma Vinod K. , Clemons Tristan D. , Beevi Syed S. , Hay Trevor , Mahidhara Ganesh , Raja Meera , Nair Rekha A. , Alexander Liza E. , Patel Anant B. , Jose Jedy , Smith Nicole M. , Zdyrko Bogdan , Bourdoncle Anne , Luzinov Igor , Iyer K. Swaminathan , Clarke Alan R. , Dinesh Kumar Lekha
Published: April 2023

Supplementary Figure S6: Densitometric analysis of immunoblots from Figure 2, Figure 3E and Figure 4C.
Supplementary Figure Legends from Targeting c-MYC in Platinum-Resistant Ovarian Cancer
Authors: Reyes-González Jeyshka M. , Armaiz-Peña Guillermo N. , Mangala Lingegowda S. , Valiyeva Fatma , Ivan Cristina , Pradeep Sunila , Echevarría-Vargas Ileabett M. , Rivera-Reyes Adrian , Sood Anil K. , Vivas-Mejía Pablo E.
Published: April 2023

Supplementary figure legends.
Supplemental Figures 1-4 from Validation of the Hsp70–Bag3 Protein–Protein Interaction as a Potential Therapeutic Target in Cancer
Authors: Li Xiaokai , Colvin Teresa , Rauch Jennifer N. , Acosta-Alvear Diego , Kampmann Martin , Dunyak Bryan , Hann Byron , Aftab Blake T. , Murnane Megan , Cho Min , Walter Peter , Weissman Jonathan S. , Sherman Michael Y. , Gestwicki Jason E.
Published: April 2023

Supplemental Figures 1-4. Supplemental Figure 1. Chemical structures of the compounds used in this study and characterization of JG98-biotin by NMR and MS/MS; Supplemental Figure 2. JG-98 disrupts the Hsp70-Bag interaction in HeLa cells; Supplemental Figure 3. Additional information on the viability of cells treated with YM-01 or JG-98; Supplemental Figure 4. Pharmacokinetics parameters for JG-98 and results of blood analysis for liver and renal function.
Suppl Table 2 from Antitumor Activity of the MEK Inhibitor TAK-733 against Melanoma Cell Lines and Patient-Derived Tumor Explants
Authors: Micel Lindsey N. , Tentler John J. , Tan Aik-Choon , Selby Heather M. , Brunkow Kelsey L. , Robertson Kelli M. , Davis S. Lindsey , Klauck Peter J. , Pitts Todd M. , Gangolli Esha , Fabrey Robyn , O'Connell Shawn M. , Vincent Patrick W. , Eckhardt S. Gail
Published: April 2023

Suppl Table 2. TAK-733 PD/ Conc. Summary, A375 tumor bearing nude mouse
Supplementary Figure S2 from Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer
Authors: Shah Khyati N. , Wilson Elizabeth A. , Malla Ritu , Elford Howard L. , Faridi Jesika S.
Published: April 2023

Supplementary Fig. S2: Stable overexpression of RRM2 reduces tamoxifen sensitivity in MCF-7 breast cancer cells.